Sarcomatoid features (SF) in renal cell carcinoma (RCC) denote poor prognosis. Data for metastatic chromophobe RCC (ChRCC) with SF are limited. We studied clinical outcomes and genomic features in this setting. We performed a retrospective review of newly diagnosed metastatic ChRCC patients; end points included overall survival (OS), time to treatment failure (TTF), and time to metastatic recurrence (TTR) after nephrectomy for localized disease. A subset of patients underwent next-generation sequencing (NGS). Outcomes were compared using nonparametric tests. One hundred nine patients with metastatic ChRCC were identified including 29 with SF. Median TTR after nephrectomy was shorter for patients with versus without SF (2.7 months 95% confidence interval (CI), 0.7-6.9 versus 48.8 months 95% CI, 30.8-80.7, log rank P < .001). Median TTF during first-line therapy was shorter for patients with versus without SF (1.8 months 95% CI, 0.9-2.7 vs. 8.0 months 95% CI, 5.1-13.0; log rank P < .001). No responses were observed in 6 patients treated with nivolumab including 4 with SF. Median OS was inferior for patients with versus without SF (38 months vs.7.5 months; hazard ratio, 4.7 95% CI, 2.7-8.2; P < .001). NGS, performed in 22 patients, showed that 64% and 45% harbored tumor protein P53 and phosphatase and tensin homolog alterations, respectively. Microsatellite instability high status was identified in 3 patients. Metastatic ChRCC patients with SF had worse outcomes compared with those without SF. Median TTR < 3 months for this subgroup supports close surveillance after nephrectomy for localized tumors. Lack of benefit with various systemic regimens warrants studying underlying biology and investigating novel agents. We studied cancer-specifics outcomes of 109 patients with metastatic chromophobe renal cell carcinoma with and without sarcomatoid features. We found that patients with metastatic sarcomatoid chromophobe renal cell carcinoma had uniformly poor outcomes with a short time to recurrence with metastatic disease after nephrectomy, limited response to systemic therapy, and poor overall survival compared with those without sarcomatoid features.